Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Blood Test for Protein Biomarker Could Detect Pancreatic Cancer at Very Early Stage

By LabMedica International staff writers
Posted on 02 Dec 2022

Pancreatic cancer initially produces only diffuse symptoms and is therefore often detected so late that it is difficult to treat successfully. More...

As a result, the mortality rate for this form of cancer is very high. The only effective treatment at present is surgery. For it to be effective, the cancer must not have spread outside the pancreas. Finding ways to detect pancreatic cancer earlier would be an important step towards treating it before it is too late, and thus saving lives. Now, a new study has found that in some people diagnosed with pancreatic cancer, levels of a particular substance in their blood can be seen to start rising slowly as early as two years before the cancer was diagnosed. This raises the possibility for future research to find ways to detect the dreaded cancer earlier.

In the study, researchers at Umeå University (Umeå, Sweden) used the blood donated to the research by people in north of Sweden over several decades, and they are now showing that this is a research resource of a magnitude that has few equals in the world. There are already two known markers in the blood for pancreatic cancer, two proteins called CA19-9 and CEA, respectively. They are effective in monitoring the development of the cancer once it is established.

The researchers therefore systematically searched the biobank for people who later developed pancreatic cancer and measured markers in their blood that could show that the cancer was coming. What they found was that a small proportion of people who developed pancreatic cancer had slowly rising levels of the CA19-9 marker from two years before they were diagnosed with the cancer. However, the researchers were unable to find a marker that was sufficiently early to predict which healthy people were at risk of later developing the cancer. None of the markers they looked for was sensitive enough to be used for general population-level screening.

“The finding suggests that changes occur in the body even before symptoms of the disease make themselves known, said Daniel Öhlund,” Associate Professor at the Department of Radiation Sciences and one of the researchers behind the study.

“The study shows that with the right markers, it may be possible to detect pancreatic cancer earlier than we do today, and that would be very valuable,” added Malin Sund, Professor at the Department of Surgical and Perioperative Sciences, who led the work on the current study.

“There is potential for a blood test to detect pancreatic cancer at a very early stage, but that we need to find more sensitive markers for the disease than we currently have,” said James Mason, one of the study's lead authors.

Related Links:
Umeå University


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.